Advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression.
VIEW PRODUCT PIPELINEAbout
We are a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders.
Read MoreNews
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
April 16, 2024
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 10, 2024
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 4, 2024
Product Pipeline
XEN1101
for Focal Onset Seizures (FOS)
X-TOLE2/3 Clinical Trial
XEN1101
for Primary Generalized Tonic-Clonic Seizures (PGTCS)
X-ACKT Clinical Trial
XEN1101
for Major Depressive Disorder (MDD)
X-NOVA Clinical trial
XEN1101
for MDD
Investigator-led Phase 2 POC study Collaboration with Mount Sinai
NBI-921352
for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area